NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer - NICE TAG TA395

Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer - NICE TAG TA395

1.1 Ceritinib is recommended, within its marketing authorisation, as an option for treating advanced anaplastic lymphoma kinase positive non‑small‑cell lung cancer in adults who have previously had crizotinib. The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/ta395 

Site by Devopa
© Copyright 2019 NHS. All rights reserved.